Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:

Published byΔαρείος Παπανδρέου Modified over 5 years ago

Similar presentations

Presentation on theme: "Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:"— Presentation transcript:

1 Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis.
Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A: qPCR of gluconeogenic gene expression. B: Blood glucose levels from Ad-GFP– and Ad-Btg2–infected mice for 7 days (n = 4–6). C and D: Glucose and insulin tolerance tests from mice infected with Ad-Btg2 at day 4 intravenously. *P < 0.05; **P < 0.01 vs. Ad-GFP. AUC, area under the curve. Yong Deuk Kim et al. Diabetes 2014;63: ©2014 by American Diabetes Association

Download ppt "Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:"

Similar presentations

Postprandial glucose flux in nondiabetic controls.

Postprandial glucose flux in nondiabetic controls.
Expression of NCoR1∆ID in PAX8−/− mice does not reverse repression of T3-positive target genes. qPCR on the indicated pituitary (A) and neuronal (B) genes.

Expression of NCoR1∆ID in PAX8−/− mice does not reverse repression of T3-positive target genes. qPCR on the indicated pituitary (A) and neuronal (B) genes.
MRNA expression levels of the gene encoding CAR in explanted human islets from control donors, cultured in UV-treated culture medium derived from CBV-infected.

MRNA expression levels of the gene encoding CAR in explanted human islets from control donors, cultured in UV-treated culture medium derived from CBV-infected.
Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.
MRNA expression levels of the gene encoding CAR in isolated human islets from control donors, cultured for prolonged time (n=2). mRNA expression levels.

MRNA expression levels of the gene encoding CAR in isolated human islets from control donors, cultured for prolonged time (n=2). mRNA expression levels.
VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.

VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.
BTG2 regulates gluconeogenic gene expression in diabetic mouse models

BTG2 regulates gluconeogenic gene expression in diabetic mouse models
Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.
BTG2-mediated hepatic gluconeogenesis is mediated by Nur77.

BTG2-mediated hepatic gluconeogenesis is mediated by Nur77.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.
1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.
Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.
TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.
GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.
Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.
Activation of β-adrenoceptors improves glucose tolerance in diabetic animals and increases glucose uptake in vivo, ex vivo, and in vitro. Activation of.

Activation of β-adrenoceptors improves glucose tolerance in diabetic animals and increases glucose uptake in vivo, ex vivo, and in vitro. Activation of.
Sox4 promotes hepatic TG accumulation in vivo.

Sox4 promotes hepatic TG accumulation in vivo.
A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:
Gyk regulates the hepatic glycerol gluconeogenesis axis and the AKT-FOXO1-PEPCK/G6Pase pathway. Gyk regulates the hepatic glycerol gluconeogenesis axis.

Gyk regulates the hepatic glycerol gluconeogenesis axis and the AKT-FOXO1-PEPCK/G6Pase pathway. Gyk regulates the hepatic glycerol gluconeogenesis axis.

Similar presentations

Ads by Google